GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » EV-to-EBITDA

Shanghai Junshi Biosciences Co (HKSE:01877) EV-to-EBITDA : -20.59 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shanghai Junshi Biosciences Co's enterprise value is HK$26,039.9 Mil. Shanghai Junshi Biosciences Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1,264.8 Mil. Therefore, Shanghai Junshi Biosciences Co's EV-to-EBITDA for today is -20.59.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's EV-to-EBITDA or its related term are showing as below:

HKSE:01877' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50.05   Med: -8.38   Max: -4.33
Current: -20.59

During the past 8 years, the highest EV-to-EBITDA of Shanghai Junshi Biosciences Co was -4.33. The lowest was -50.05. And the median was -8.38.

HKSE:01877's EV-to-EBITDA is ranked worse than
100% of 465 companies
in the Biotechnology industry
Industry Median: 9.34 vs HKSE:01877: -20.59

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Shanghai Junshi Biosciences Co's stock price is HK$12.62. Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1.269. Therefore, Shanghai Junshi Biosciences Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Shanghai Junshi Biosciences Co EV-to-EBITDA Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co EV-to-EBITDA Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -26.75 -25.98 -131.82 -16.28 -7.28

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.42 -6.01 -6.49 -7.28 -6.41

Competitive Comparison of Shanghai Junshi Biosciences Co's EV-to-EBITDA

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's EV-to-EBITDA falls into.



Shanghai Junshi Biosciences Co EV-to-EBITDA Calculation

Shanghai Junshi Biosciences Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=26039.864/-1264.84
=-20.59

Shanghai Junshi Biosciences Co's current Enterprise Value is HK$26,039.9 Mil.
Shanghai Junshi Biosciences Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1,264.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Shanghai Junshi Biosciences Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.62/-1.269
=At Loss

Shanghai Junshi Biosciences Co's share price for today is HK$12.62.
Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1.269.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Shanghai Junshi Biosciences Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines